Detalhe da pesquisa
1.
Everolimus in patients with autosomal dominant polycystic kidney disease.
N Engl J Med
; 363(9): 830-40, 2010 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-20581392
2.
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Lancet
; 377(9768): 837-47, 2011 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-21334736
3.
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.
J Clin Invest
; 110(9): 1309-18, 2002 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-12417570
4.
The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.
Eur J Pharmacol
; 560(1): 1-8, 2007 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-17316606
5.
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
J Clin Oncol
; 23(30): 7583-93, 2005 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16234522
6.
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
Cancer Lett
; 233(2): 328-37, 2006 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-15893416
7.
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Clin Cancer Res
; 9(13): 4674-81, 2003 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14581336
8.
Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.
Keio J Med
; 52(3): 182-8, 2003 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-14529151
9.
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
Ann N Y Acad Sci
; 996: 26-38, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12799279
10.
Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers.
Ther Drug Monit
; 28(3): 312-20, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16778713
11.
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood
; 108(5): 1469-77, 2006 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16638934
12.
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood
; 106(2): 458-63, 2005 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15817679
13.
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Blood
; 105(1): 335-40, 2005 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15345593
14.
Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study.
Lancet
; 359(9305): 481-6, 2002 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-11853794
15.
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Blood
; 102(2): 659-61, 2003 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12663457
16.
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
Blood
; 101(1): 85-90, 2003 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12393581
17.
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Blood
; 101(8): 2960-2, 2003 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12480706
18.
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
Blood
; 99(5): 1860-2, 2002 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11861307
19.
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
Blood
; 103(10): 3644-54, 2004 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14726395
20.
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Blood
; 101(1): 259-64, 2003 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12393722